Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2020

11.10.2019 | Thoracic Oncology

How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?

verfasst von: Jonathan C. Yeung, MD, Manjit S. Bains, MD, Arianna Barbetta, MD, Tamar Nobel, MD, Steven R. DeMeester, MD, Brian E. Louie, MD, Mark B. Orringer, MD, Linda W. Martin, MD, Rishindra M. Reddy, MD, Francisco Schlottmann, MD, Daniela Molena, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction and Design

Node dissection during esophagectomy is an important aspect of esophageal cancer staging. Controversy remains as to how many nodes need to be resected in order to properly stage a patient and whether the removal of more nodes carries a stage-independent survival benefit. A review of the literature performed by a group of experts in the subject may help define a minimum accepted number of lymph nodes to be resected in both primary surgery and post-induction therapy scenarios.

Results and Conclusions

The existing evidence generally supports the goal of obtaining a minimum of 15 lymph nodes for pathological examination in both primary surgery and post-induction therapy scenarios.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.CrossRef Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.CrossRef
2.
Zurück zum Zitat Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus. 2004;17:310–4.CrossRef Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus. 2004;17:310–4.CrossRef
3.
Zurück zum Zitat Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139:612–20.CrossRef Groth SS, Virnig BA, Whitson BA, et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139:612–20.CrossRef
4.
Zurück zum Zitat Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.CrossRef Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.CrossRef
5.
Zurück zum Zitat Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384–93; discussion 1393–4.CrossRef Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384–93; discussion 1393–4.CrossRef
6.
Zurück zum Zitat Samson P, Puri V, Robinson C, et al. Clinical T2N0 Esophageal cancer: identifying pretreatment characteristics associated with pathologic upstaging and the potential role for induction therapy. Ann Thorac Surg. 2016;101:2102–11.CrossRef Samson P, Puri V, Robinson C, et al. Clinical T2N0 Esophageal cancer: identifying pretreatment characteristics associated with pathologic upstaging and the potential role for induction therapy. Ann Thorac Surg. 2016;101:2102–11.CrossRef
7.
Zurück zum Zitat Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRef Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRef
8.
Zurück zum Zitat Bollschweiler E, Baldus SE, Schroder W, Schneider PM, Holscher AH. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94:355–63.CrossRef Bollschweiler E, Baldus SE, Schroder W, Schneider PM, Holscher AH. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94:355–63.CrossRef
9.
Zurück zum Zitat Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132:1374–81.CrossRef Rizk N, Venkatraman E, Park B, et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132:1374–81.CrossRef
10.
Zurück zum Zitat Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRef Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRef
11.
Zurück zum Zitat Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRef Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRef
12.
Zurück zum Zitat Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN +) lymph node metastases. Ann Surg. 2017;265:122–9.CrossRef Rice TW, Ishwaran H, Hofstetter WL, et al. Esophageal cancer: associations with (pN +) lymph node metastases. Ann Surg. 2017;265:122–9.CrossRef
13.
Zurück zum Zitat Lagergren J, Mattsson F, Zylstra J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2016;151:32–9.CrossRef Lagergren J, Mattsson F, Zylstra J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2016;151:32–9.CrossRef
14.
Zurück zum Zitat van der Schaaf M, Johar A, Wijnhoven B, Lagergren P, Lagergren J. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015;107:pii:djv043. van der Schaaf M, Johar A, Wijnhoven B, Lagergren P, Lagergren J. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015;107:pii:djv043.
15.
Zurück zum Zitat Alatengbaolide, Lin D, Li Y, et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am J Clin Oncol. 2013;36:325–30.CrossRef Alatengbaolide, Lin D, Li Y, et al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am J Clin Oncol. 2013;36:325–30.CrossRef
16.
Zurück zum Zitat Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V. Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. Cancer. 2016;122:1388–97.CrossRef Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V. Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. Cancer. 2016;122:1388–97.CrossRef
17.
Zurück zum Zitat Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg. 2008;206:239–46.CrossRef Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg. 2008;206:239–46.CrossRef
18.
Zurück zum Zitat Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520–30; discussion 530–1.CrossRef Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520–30; discussion 530–1.CrossRef
19.
Zurück zum Zitat Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–8.CrossRef Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:872–8.CrossRef
20.
Zurück zum Zitat Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–32.CrossRef Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–32.CrossRef
21.
Zurück zum Zitat Hu Y, Hu C, Zhang H, Ping Y, Chen LQ. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010;17:784–90.CrossRef Hu Y, Hu C, Zhang H, Ping Y, Chen LQ. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma? Ann Surg Oncol. 2010;17:784–90.CrossRef
22.
Zurück zum Zitat Peng J, Wang WP, Yuan Y, Wang ZQ, Wang Y, Chen LQ. Adequate lymphadenectomy in patients with oesophageal squamous cell carcinoma: resecting the minimal number of lymph node stations. Eur J Cardiothorac Surg. 2016;49:e141–6.CrossRef Peng J, Wang WP, Yuan Y, Wang ZQ, Wang Y, Chen LQ. Adequate lymphadenectomy in patients with oesophageal squamous cell carcinoma: resecting the minimal number of lymph node stations. Eur J Cardiothorac Surg. 2016;49:e141–6.CrossRef
23.
Zurück zum Zitat Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB Jr, Meyers BF; American College of Surgeons Oncology Group ZT. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008;86:418–21; discussion 421. Veeramachaneni NK, Zoole JB, Decker PA, Putnam JB Jr, Meyers BF; American College of Surgeons Oncology Group ZT. Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Ann Thorac Surg. 2008;86:418–21; discussion 421.
24.
Zurück zum Zitat Abbassi-Ghadi N, Boshier PR, Goldin R, Hanna GB. Techniques to increase lymph node harvest from gastrointestinal cancer specimens: a systematic review and meta-analysis. Histopathology. 2012;61:531–42.CrossRef Abbassi-Ghadi N, Boshier PR, Goldin R, Hanna GB. Techniques to increase lymph node harvest from gastrointestinal cancer specimens: a systematic review and meta-analysis. Histopathology. 2012;61:531–42.CrossRef
25.
Zurück zum Zitat Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.CrossRef Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.CrossRef
26.
Zurück zum Zitat Markl B. Stage migration vs immunology: the lymph node count story in colon cancer. World J Gastroenterol. 2015;21:12218–33.CrossRef Markl B. Stage migration vs immunology: the lymph node count story in colon cancer. World J Gastroenterol. 2015;21:12218–33.CrossRef
27.
Zurück zum Zitat Luna RA, Dolan JP, Diggs BS, et al. Lymph node harvest during esophagectomy is not influenced by use of neoadjuvant therapy or clinical disease stage. J Gastrointest Surg. 2015;19:1201–7.CrossRef Luna RA, Dolan JP, Diggs BS, et al. Lymph node harvest during esophagectomy is not influenced by use of neoadjuvant therapy or clinical disease stage. J Gastrointest Surg. 2015;19:1201–7.CrossRef
28.
Zurück zum Zitat Taylor MD, LaPar DJ, Davis JP, et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann Thorac Surg. 2013;96:225–30; discussion 230–1.CrossRef Taylor MD, LaPar DJ, Davis JP, et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann Thorac Surg. 2013;96:225–30; discussion 230–1.CrossRef
29.
Zurück zum Zitat Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRef Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRef
30.
Zurück zum Zitat Kauppila JH, Wahlin K, Lagergren P, Lagergren J. Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer. Sci Rep. 2018;8:446.CrossRef Kauppila JH, Wahlin K, Lagergren P, Lagergren J. Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer. Sci Rep. 2018;8:446.CrossRef
31.
Zurück zum Zitat van der Werf LR, Dikken JL, van Berge Henegouwen MI, et al. A population-based study on lymph node retrieval in patients with esophageal cancer: results from the Dutch upper gastrointestinal cancer audit. Ann Surg Oncol. 2018;25:1211–20.CrossRef van der Werf LR, Dikken JL, van Berge Henegouwen MI, et al. A population-based study on lymph node retrieval in patients with esophageal cancer: results from the Dutch upper gastrointestinal cancer audit. Ann Surg Oncol. 2018;25:1211–20.CrossRef
32.
Zurück zum Zitat Brescia AA, Broderick SR, Crabtree TD, et al. Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg. 2016;101:200–8.CrossRef Brescia AA, Broderick SR, Crabtree TD, et al. Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg. 2016;101:200–8.CrossRef
33.
Zurück zum Zitat Hanna JM, Erhunmwunsee L, Berry M, et al. The prognostic importance of the number of dissected lymph nodes after induction chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2015;99:265–9.CrossRef Hanna JM, Erhunmwunsee L, Berry M, et al. The prognostic importance of the number of dissected lymph nodes after induction chemoradiotherapy for esophageal cancer. Ann Thorac Surg. 2015;99:265–9.CrossRef
34.
Zurück zum Zitat Samson P, Puri V, Broderick S, Patterson GA, Meyers B, Crabtree T. Extent of lymphadenectomy is associated with improved overall survival after esophagectomy with or without induction therapy. Ann Thorac Surg. 2017;103:406–15.CrossRef Samson P, Puri V, Broderick S, Patterson GA, Meyers B, Crabtree T. Extent of lymphadenectomy is associated with improved overall survival after esophagectomy with or without induction therapy. Ann Thorac Surg. 2017;103:406–15.CrossRef
Metadaten
Titel
How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?
verfasst von
Jonathan C. Yeung, MD
Manjit S. Bains, MD
Arianna Barbetta, MD
Tamar Nobel, MD
Steven R. DeMeester, MD
Brian E. Louie, MD
Mark B. Orringer, MD
Linda W. Martin, MD
Rishindra M. Reddy, MD
Francisco Schlottmann, MD
Daniela Molena, MD
Publikationsdatum
11.10.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07870-2

Weitere Artikel der Ausgabe 4/2020

Annals of Surgical Oncology 4/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.